Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism After Elective Total Hip Replacement Surgery
Phase of Trial: Phase III
Latest Information Update: 17 May 2017
At a glance
- Drugs Fondaparinux sodium (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 12 Jun 2007 Status changed from recruiting to completed.
- 31 May 2007 New trial record.